We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Controlling particulate matter in injectable drug products has long been a cornerstone of patient safety. While large visible particles often gain public attention through recalls, subvisible particulate contamination the particles you can’t see pose an equally serious risk. These particles can compromise product quality, trigger inflammation or immune reactions, and jeopardize the safety of sensitive patient populations.
One of the most important regulatory safeguards in this area is USP <788> Particulate Matter in Injections, a globally harmonized chapter that guides how parenteral drug products are assessed for subvisible particles. With significant updates becoming official on August 1, 2026, and increasing scrutiny from global regulatory agencies, now is the time for manufacturers to strengthen their understanding and readiness.
USP published the latest revision in NF 2026 Issue 3 on November 21, 2025. While the foundational principles of particulate control remain intact, several important refinements will impact how manufacturers design, test, and justify their particulate strategies.
Key updates include:
These changes do not alter the core principle: manufacturers must understand, assess, and control particulate matter to protect patients.
Three major forces are driving an elevated emphasis on particulate control:
USP <788> is harmonized with:
This means manufacturers around the world follow the same particle size thresholds, testing methods, and acceptance criteria, creating global consistency. It also means component suppliers must operate at this international standard to ensure broad product compatibility.
USP <788> applies to the finished injectable product, yet particulate matter can enter the process at many stages across the supply chain. Primary packaging components such as glass containers and elastomer stoppers or plungers are one of several potential contributors to the overall particulate profile simply because they come into direct contact with the drug product. Their contribution can depend on factors such as material characteristics, component preparation, washing and sterilization processes, transportation, and longterm storage conditions. Recognizing this, regulatory guidance aligned with USP emphasizes that component quality and supplier controls form an important part of a broader contamination control strategy, alongside many other upstream and downstream factors.
These particles can shed during:
Regulators acknowledge this. Guidance aligned with USP stresses that component quality and supplier controls directly impact a drug's particulate profile, making packaging selection a central element of a robust contamination control strategy.
This is where the link to EU GMP Annex 1 becomes essential.
While USP sets the limits, Annex 1 governs the systems and controls needed to consistently meet them.
Under Annex 1, manufacturers must build a Contamination Control Strategy (CCS) that encompasses:
Primary packaging because it directly contacts sterile drug product plays a pivotal role in this strategy. Annex 1 requires packaging manufacturers to demonstrate that their materials, processes, and controls minimize the risk of microbial, pyrogenic, and particulate contamination.
This makes packaging a core line of defence in particulate management not a passive container.
Industry data highlights the connection between packaging and particulate failures. 37% of FDA injectable drug recalls were due to particulate or lack of sterility attributable to container closure1
When components shed particles, consequences may include:
This is why high-quality components designed for low particulate contribution are essential not optional.
NovaPure® components are engineered to give manufacturers a clean, low particulate baseline precisely what USP <788> compliance depends on.
Because USP <788> counts all subvisible particle types—including those originating from packaging every particle shed by a component reduces the margin for compliance. NovaPure® minimizes this risk through:
Most importantly, NovaPure® typically contributes less than 3.5% of the total allowable particulate limit under USP <788>, giving manufacturers a significantly cleaner starting point.
The result: a component platform that supports both USP <788> requirements and Annex 1’s contamination control expectations, helping pharmaceutical companies protect patients and safeguard product quality.
English
Chinese
